Physician

Paul J Russinko, M.D.

According to 2025 Medicare claims, Paul Russinko, M.D. (NPI: 1720041981) practices urology in the Lancaster, PA market, with the plurality of this provider's patient population coming from Lancaster, PA. This provider's primary affiliated billing organization is THE CENTERS FOR ADVANCED UROLOGY, LLP (NPI: 1295565356; TIN: 474352018) and primary practice location at 17604-3200. Russinko is affiliated with the Lancaster General Health Community Care Collaborative, LLC (ACO ID: A2019), participating under the MSSP model.

Russinko's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,084 traditional Medicare patients, billed 30,834 HCPCS/CPT codes, and received $582,667 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,165 prescription claims across 619 beneficiaries totaling $274,860 in drug costs, led by Myrbetriq (Mirabegron). DME data shows 38 claims. Open Payments data shows 27 records totaling $509. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $189,264 to $582,667. Concurrently, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $800 and ending at $260.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	837	6,955	$189,264
2016	832	7,936	$190,276
2017	780	7,299	$272,603
2018	808	9,572	$227,426
2019	858	9,063	$231,968
2020	701	13,523	$161,657
2021	920	16,436	$289,218
2022	1,225	15,412	$324,359
2023	1,396	17,012	$339,301
2024	2,084	30,834	$582,667

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	474	1,822	$196,280
2016	500	1,802	$206,367
2017	498	1,780	$188,798
2018	509	1,827	$235,311
2019	542	2,190	$257,427
2020	524	2,113	$215,562
2021	560	2,017	$203,033
2022	560	2,116	$242,609
2023	575	2,115	$256,931
2024	619	2,165	$274,860

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	104	$12,211
2016	N/R	43	$7,565
2017	N/R	54	$7,842
2018	N/R	29	$23,153
2019	N/R	42	$30,142
2020	N/R	117	$21,301
2021	49	171	$15,127
2022	98	175	$25,347
2023	N/R	47	$30,356
2024	N/R	38	$31,234

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	1,017	1,292	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	853	1,054	$56
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	771	1,021	$12
81001	Manual urinalysis test with examination using microscope, automated	697	783	$3
81003	Automated urinalysis test	600	708	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Myrbetriq	Mirabegron	153	9,657	$139,403
Orgovyx	Relugolix	17	510	$43,799
Gemtesa	Vibegron	40	2,170	$34,385
Alfuzosin Hcl Er	Alfuzosin Hcl	351	26,012	$8,302
Dutasteride	Dutasteride	126	10,114	$5,918

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4352	Intermittent urinary catheter; coude (curved) tip, with or without coating (teflon, silicone, silicone elastomeric, or hydrophilic, etc.), each	N	N/R	18	$27,014
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	N/R	20	$4,220

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	27	$509	UROGEN PHARMA, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul J. Russinko, M.D.?

Tedicare shows public-source Medicare data for Paul J. Russinko, M.D. (NPI 1720041981), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul J. Russinko, M.D. have ACO affiliation data?

Paul J. Russinko, M.D. is shown with ACO affiliation data for Lancaster General Health Community Care Collaborative, LLC (MSSP, ACO ID A2019).

What billing organization is linked to Paul J. Russinko, M.D.?

Paul J. Russinko, M.D. is linked to THE CENTERS FOR ADVANCED UROLOGY, LLP (billing NPI 1295565356) in the available physician profile data.

Does Paul J. Russinko, M.D. have Open Payments data?

Paul J. Russinko, M.D. has 27 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.